Natural killer T cells: Drivers or passengers in preventing human disease?

Nature Reviews Immunology

Volumn 14, Issue 9, 2014, Pages 640-646

  Berzins, Stuart P ^a,b,c   Ritchie, David S ^c,d  

^a UNIVERSITY OF BALLARAT   (Australia)

^b Fiona Elsey Cancer Research Institute   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR ANTIGEN; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ALLERGY; AUTOIMMUNE DISEASE; CANCER IMMUNOLOGY; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANTIGEN PRESENTING CELL; ASTHMA; CYTOKINE RELEASE; DISEASE MARKER; DISEASES; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH HAZARD; IMMUNE RESPONSE; NEOPLASM; TH1 CELL; ANIMAL; ANIMAL MODEL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOUSE; SECRETION (PROCESS);

ANIMALS; ANTIGENS, CD1D; ASTHMA; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MODELS, ANIMAL; NATURAL KILLER T-CELLS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 84906933853     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3725     Document Type: Review

References (124)

1. Bendelac, A., Savage, P. B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336 (2007). (Pubitemid 46697911)
2. Salio, M., Silk, J. D., Yvonne Jones, E. & Cerundolo, V. Biology of CD1-and MR1-restricted T cells. Annu. Rev. Immunol. 32, 323-366 (2014).
3. Berzins, S. P., Smyth, M. J. & Baxter, A. G. Presumed guilty: natural killer T cell defects and human disease. Nature Rev. Immunol. 11, 131-142 (2011).
4. Exley, M. A. & Nakayama, T. NKT-cell-based immunotherapies in clinical trials. Clin. Immunol. 140, 117-118 (2011).
5. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Van Kaer, L. NKT cells: what's in a name? Nature Rev. Immunol. 4, 231-237 (2004).
6. Godfrey, D. I., Stankovic, S. & Baxter, A. G. Raising the NKT cell family. Nature Immunol. 11, 197-206 (2010).
7. Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L. & Godfrey, D. I. Recognition of CD1d-restricted antigens by natural killer T cells. Nature Rev. Immunol. 12, 845-857 (2012).
8. Godfrey, D. I. & Rossjohn, J. New ways to turn on NKT cells. J. Exp. Med. 208, 1121-1125 (2011).
9. Kinjo, Y. et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nature Immunol. 12, 966-974 (2011).
10. Kinjo, Y. et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nature Immunol. 7, 978-986 (2006). (Pubitemid 44263912)
11. Mattner, J. et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434, 525-529 (2005). (Pubitemid 40477062)
12. Brennan, P. J., Brigl, M. & Brenner, M. B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nature Rev. Immunol. 13, 101-117 (2013).
13. Gapin, L., Godfrey, D. I. & Rossjohn, J. Natural killer T cell obsession with self-antigens. Curr. Opin. Immunol. 25, 168-173 (2013).
14. Holzapfel, K. L., Tyznik, A. J., Kronenberg, M. & Hogquist, K. A. Antigen-dependent versus-independent activation of invariant NKT cells during infection. J. Immunol. 192, 5490-5498 (2014).
15. Crowe, N. Y. et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202, 1279-1288 (2005). (Pubitemid 41586958)
16. Lee, P. T., Benlagha, K., Teyton, L. & Bendelac, A. Distinct functional lineages of human Va24 natural killer T cells. J. Exp. Med. 195, 637-641 (2002). (Pubitemid 34461508)
17. Kim, C. H., Butcher, E. C. & Johnston, B. Distinct subsets of human Va24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol. 23, 516-519 (2002). (Pubitemid 35223543)
18. Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195, 625-636 (2002). (Pubitemid 34461507)
19. Berzofsky, J. A. & Terabe, M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180, 3627-3635 (2008).
20. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nature Rev. Immunology 12, 239-252 (2012).
21. Dhodapkar, M. V. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front. Biosci. 14, 796-807 (2009).
22. Novak, J., Griseri, T., Beaudoin, L. & Lehuen, A. Regulation of type 1 diabetes by NKT cells. Int. Rev. Immunol. 26, 49-72 (2007). (Pubitemid 46512166)
23. Fletcher, M. T. & Baxter, A. G. Clinical application of NKT cell biology in type I (autoimmune) diabetes mellitus. Immunol. Cell Biol. 87, 315-323 (2009).
24. Lehuen, A., Diana, J., Zaccone, P. & Cooke, A. Immune cell crosstalk in type 1 diabetes. Nature Rev. Immunol. 10, 501-513 (2010).
25. Kim, H. Y., DeKruyff, R. H. & Umetsu, D. T. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nature Immunol. 11, 577-584 (2010).
26. Holtzman, M. J. Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J. Clin. Invest. 122, 2741-2748 (2012).
27. Umetsu, D. T. & Dekruyff, R. H. Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J. Allergy Clin. Immunol. 125, 975-979 (2010).
28. Swann, J. B., Coquet, J. M., Smyth, M. J. & Godfrey, D. I. CD1-restricted T cells and tumor immunity. Curr. Top. Microbiol. Immunol. 314, 293-323 (2007).
29. Terabe, M. & Berzofsky, J. A. The role of NKT cells in tumor immunity. Adv. Cancer Res. 101, 277-348 (2008).
30. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
31. Swann, J. B. et al. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113, 6382-6385 (2009).
32. Molling, J. W. et al. Peripheral blood IFN-.-secreting Va24+Vß11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116, 87-93 (2005). (Pubitemid 40827759)
33. Gulubova, M., Manolova, I., Kyurkchiev, D., Julianov, A. & Altunkova, I. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS 117, 870-879 (2009).
34. Konishi, J. et al. The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum. Immunol. 65, 1377-1388 (2004). (Pubitemid 39539204)
35. Molling, J. W. et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25, 862-868 (2007). (Pubitemid 350002887)
36. de Lalla, C. et al. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4-subset dynamics and correlates with remission state. J. Immunol. 186, 4490-4499 (2011).
37. Rubio, M. T. et al. Early posttransplantation donorderived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 120, 2144-2154 (2012).
38. Yamasaki, K. et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT celltargeted adoptive immunotherapy. Clin. Immunol. 138, 255-265 (2011).
39. Fujii, S. I. et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front. Immunol. 4, 409 (2013).
40. Fletcher, J. M. et al. Congenic analysis of the NKT cell control gene Nkt2 implicates the peroxisomal protein Pxmp4. J. Immunol. 181, 3400-3412 (2008).
41. Wu, L. & Van Kaer, L. Natural killer T cells and autoimmune disease. Curr. Mol. Med. 9, 4-14 (2009).
42. Simoni, Y., Diana, J., Ghazarian, L., Beaudoin, L. & Lehuen, A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin. Exp. Immunol. 171, 8-19 (2013).
43. Akbari, O. et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N. Engl. J. Med. 354, 1117-1129 (2006).
44. Matangkasombut, P. et al. Natural killer T cells in the lungs of patients with asthma. J. Allergy Clin. Immunol. 123, 1181-1185 (2009).
45. Vijayanand, P. et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 1410-1422 (2007). (Pubitemid 46556326)
46. Reynolds, C. et al. Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma. J. Allergy Clin. Immunol. 124, 860-862 (2009).
47. Brooks, C. R., Weinkove, R., Hermans, I. F., van Dalen, C. J. & Douwes, J. Invariant natural killer T cells and asthma: immunologic reality or methodologic artifact? J. Allergy Clin. Immunol. 126, 882-885 (2010).
48. van der Vliet, H. J. J. et al. Circulating Va24+ Vß11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100, 144-148 (2001).
49. Berzins, S. P., Cochrane, A. D., Pellicci, D. G., Smyth, M. J. & Godfrey, D. I. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur. J. Immunol. 35, 1399-1407 (2005). (Pubitemid 40691421)
50. Montoya, C. J. et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122, 1-14 (2007). (Pubitemid 47222606)
51. Metelitsa, L. S. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin. Immunol. 140, 119-129 (2011).
52. Giaccone, G. et al. A phase I study of the natural killer T-cell ligand a-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702-3709 (2002). (Pubitemid 35424759)
53. Uldrich, A. P. et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175, 3092-3101 (2005). (Pubitemid 41170529)
54. Parekh, V. V., Lalani, S. & Van Kaer, L. The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol. 26, 31-48 (2007). (Pubitemid 46512168)
55. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. & Steinman, R. M. Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279 (2003). (Pubitemid 36987852)
56. Cerundolo, V., Barral, P. & Batista, F. D. Synthetic iNKT cell-agonists as vaccine adjuvants-finding the balance. Curr. Opin. Immunol. 22, 417-424 (2010).
57. Motohashi, S., Okamoto, Y., Yoshino, I. & Nakayama, T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin. Immunol. 140, 167-176 (2011).
58. Chang, D. H. et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201, 1503-1517 (2005). (Pubitemid 40664093)
59. Yu, K. O. et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of a-galactosylceramides. Proc. Natl Acad. Sci. USA 102, 3383-3388 (2005). (Pubitemid 40328054)
60. Davis, M. M. A prescription for human immunology. Immunity 29, 835-838 (2008).
61. Le Bourhis, L. et al. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol. 32, 212-218 (2011).
62. Dusseaux, M. et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117, 1250-1259 (2011).
63. Bedel, R. et al. Lower TCR repertoire diversity in Traj18-deficient mice. Nature Immunol. 13, 705-706 (2012).
64. Berzins, S. P. et al. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunol. Cell Biol. 82, 247-252 (2004). (Pubitemid 38870017)
65. Mempel, M. et al. Comparison of the T cell patterns in leprous and cutaneous sarcoid granulomas. Presence of Vα24-invariant natural killer T cells in T-cell-reactive leprosy together with a highly biased T cell receptor Vα repertoire. Am. J. Pathol. 157, 509-523 (2000). (Pubitemid 30627561)
66. Wallace, K. L. et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-γ and CXCR3 chemokines. Blood 114, 667-676 (2009).
67. Lehuen, A. et al. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188, 1831-1839 (1998). (Pubitemid 28536770)
68. Michel, M. L. et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204, 995-1001 (2007).
69. Coquet, J. M. et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc. Natl Acad. Sci. USA 105, 11287-11292 (2008).
70. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997). (Pubitemid 27516282)
71. Crowe, N. Y., Smyth, M. J. & Godfrey, D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196, 119-127 (2002). (Pubitemid 34747317)
72. Kammertoens, T., Qin, Z., Briesemeister, D., Bendelac, A. & Blankenstein, T. B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin). Int. J. Cancer 131, 1499-1508 (2012).
73. Nowak, M. et al. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide. PLoS ONE 5, e11311 (2010).
74. Kawano, T. et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl Acad. Sci. USA 95, 5690-5693 (1998). (Pubitemid 28224157)
75. Mattarollo, S. R., Kenna, T., Nieda, M. & Nicol, A. J. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Vα24+ NKT cell-mediated cytotoxicity. Int. J. Cancer 119, 1630-1637 (2006). (Pubitemid 44258769)
76. Shimizu, K., Kurosawa, Y., Taniguchi, M., Steinman, R. M. & Fujii, S. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med. 204, 2641-2653 (2007). (Pubitemid 350063944)
77. Song, L. et al. Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524-1536 (2009).
78. Motohashi, S. et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12, 6079-6086 (2006). (Pubitemid 44703772)
79. Kobayashi, K. et al. The effect of radiotherapy on NKT cells in patients with advanced head and neck cancer. Cancer Immunol. Immunother. 59, 1503-1509 (2010).
80. Song, L. et al. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J. Clin. Invest. 117, 2702-2712 (2007). (Pubitemid 47494370)
81. Lynch, L. et al. Invariant NKT cells and CD1d+ cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 39, 1893-1901 (2009).
82. Tachibana, T. et al. Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11, 7322-7327 (2005). (Pubitemid 41507690)
83. Bricard, G. et al. Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. J. Immunol. 182, 5140-5151 (2009).
84. Dhodapkar, M. V. et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197, 1667-1676 (2003). (Pubitemid 36745342)
85. Zeng, W. et al. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br. J. Haematol. 119, 803-809 (2002). (Pubitemid 35366227)
86. Fujii, S. et al. Severe and selective deficiency of interferon-gamma- producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br. J. Haematol. 122, 617-622 (2003). (Pubitemid 36995216)
87. Yoneda, K. et al. The peripheral blood Vα24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk. Res. 29, 147-152 (2005). (Pubitemid 39647508)
88. Chan, A. C. et al. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 24, 592-600 (2010).
89. Chan, A. C. et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin. Exp. Immunol. 175, 49-58 (2014).
90. Schneiders, F. L. et al. Clinical experience with alpha- galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol. 140, 130-141 (2011).
91. Hermans, I. F. et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171, 5140-5147 (2003). (Pubitemid 37432797)
92. Burdin, N., Brossay, L. & Kronenberg, M. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 29, 2014-2025 (1999). (Pubitemid 29265558)
93. van der Vliet, H. J. et al. Polarization of Vα24+ Vβ11+ natural killer T cells of healthy volunteers and cancer patients using α-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 63, 4101-4106 (2003).
94. Song, W. et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin. Cancer Res. 14, 6955-6962 (2008).
95. Zhu, D., Corral, L. G., Fleming, Y. W. & Stein, B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57, 1849-1859 (2008).
96. Chang, D. H. et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108, 618-621 (2006). (Pubitemid 44061362)
97. Motohashi, S. et al. Preserved IFN-α production of circulating Vα24 NKT cells in primary lung cancer patients. Int. J. Cancer 102, 159-165 (2002). (Pubitemid 35168029)
98. Baxter, A. G., Kinder, S. J., Hammond, K. J. L., Scollay, R. & Godfrey, D. I. Association between α-β-TCR+CD4-CD8-T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 46, 572-582 (1997). (Pubitemid 27143372)
99. Godfrey, D. I., Kinder, S. J., Silvera, P. & Baxter, A. G. Flow cytometric study of T cell development in NOD mice reveals a deficiency in αβTCR+CDR-CD8-thymocytes. J. Autoimmun 10, 279-285 (1997). (Pubitemid 27286535)
100. Poulton, L. D. & Baxter, A. G. Clinical application of NKT cell assays to the prediction of type 1 diabetes. Diabetes Metab. Res. Rev. 17, 429-435 (2001). (Pubitemid 34030745)
101. Hammond, K. J. L. et al. T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187, 1047-1056 (1998). (Pubitemid 28176405)
102. Beaudoin, L., Laloux, V., Novak, J., Lucas, B. & Lehuen, A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 17, 725-736 (2002). (Pubitemid 35477792)
103. Hong, S. et al. The natural killer T-cell ligand α- galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nature Med. 7, 1052-1056 (2001). (Pubitemid 32937387)
104. Sharif, S. et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nature Med. 7, 1057-1062 (2001). (Pubitemid 32937388)
105. Novak, J. et al. Prevention of type 1 diabetes by invariant NKT cells is independent of peripheral CD1d expression. J. Immunol. 178, 1332-1340 (2007). (Pubitemid 46156829)
106. Forestier, C. et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J. Immunol. 178, 1415-1425 (2007). (Pubitemid 46154612)
107. Ly, D., Mi, Q. S., Hussain, S. & Delovitch, T. L. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J. Immunol. 177, 3695-3704 (2006). (Pubitemid 44359901)
108. Beaudoin, L. et al. Plasmacytoid dendritic cells license regulatory T cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes. Eur. J. Immunol. 44, 1454-1466 (2014).
109. Naumov, Y. N. et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl Acad. Sci. USA 98, 13838-13843 (2001). (Pubitemid 33115985)
110. Kis, J. et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in type 1 diabetes mellitus. J. Leukoc. Biol. 81, 654-662 (2007). (Pubitemid 46393543)
111. Oikawa, Y. et al. High frequency of vα24+ vβ11+ T-cells observed in type 1 diabetes. Diabetes Care 25, 1818-1823 (2002). (Pubitemid 41071093)
112. Tsutsumi, Y. et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type 1 diabetes. Diabet Med. 23, 1145-1150 (2006). (Pubitemid 44401147)
113. Roman-Gonzalez, A. et al. Frequency and function of circulating invariant NKT cells in autoimmune diabetes mellitus and thyroid diseases in Colombian patients. Hum. Immunol. 70, 262-268 (2009).
114. Kent, S. C. et al. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J. Immunol. 175, 4458-4464 (2005). (Pubitemid 41361982)
115. Lisbonne, M. et al. Cutting edge: invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171, 1637-1641 (2003). (Pubitemid 36966444)
116. Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261-2263 (1998). (Pubitemid 29004075)
117. Herrick, C. A. & Bottomly, K. To respond or not to respond: T cells in allergic asthma. Nature Rev. Immunol. 3, 405-412 (2003). (Pubitemid 37323200)
118. Umetsu, D. T., Meyer, E. H. & DeKruyff, R. H. Natural killer T cells regulate the development of asthma. Int. Rev. Immunol. 26, 121-140 (2007). (Pubitemid 46512171)
119. Pichavant, M. et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J. Exp. Med. 205, 385-393 (2008). (Pubitemid 351281604)
120. Simoni, Y. et al. NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes. Eur. J. Immunol. 41, 3574-3585 (2011).
121. Robinson, D. S. et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326, 298-304 (1992).
122. Meyer, E. H. et al. Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc. Natl Acad. Sci. USA 103, 2782-2787 (2006).
123. Akbari, O. et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nature Med. 9, 582-588 (2003). (Pubitemid 36597105)
124. Godfrey, D. I. & Berzins, S. P. Control points in NKT-cell development. Nature Rev. Immunol. 7, 505-518 (2007). (Pubitemid 46987785)